July 03, Langenfeld, Germany - Labtec GmbH, a subsidiary of AdhexPharma specializing in drug delivery solutions, is proud to announce its involvement in the recently published article titled "A Soft Skin Adhesive (SSA) Patch for Extended Release of Pirfenidone in Burn Wounds": https://www.mdpi.com/1999-4923/15/7/1842.
The article, initiated by the Combat Wound Care Group at the US Army Institute of Surgical Research at Joint Base San Antonio-Fort Sam Houston, Texas, highlights a major breakthrough in the development of a patch for treating burn wounds using the innovative drug Pirfenidone.
The publication delves into the laboratory- and pilot-scale production process, providing valuable insights into the patch's formulation and its promising outcomes in in-vivo porcine studies. The Combat Wound Care Group's groundbreaking research aims to address the challenges of scarring and contracture commonly associated with burn wounds.
"We are honored to have been a part of the development and upscaling process," said Katja Göbel, member of the formulation department at Labtec GmbH. "This achievement showcases our commitment to advancing drug delivery systems and contributing to cutting-edge medical solutions." added Anne-Laure Tedaldi, CMC Development Director at AdhexPharma and Labtec.
About Labtec GmbH
Labtec GmbH is a subsidiary of AdhexPharma and serves as the R&D excellence center of the AdhexPharma group. Located in Germany, Labtec GmbH provides formulation, development, and contract manufacturing services for transdermal and topical patches, buccal and sublingual films. With its extensive experience and know-how, Labtec GmbH is well-positioned to support AdhexPharma's efforts to provide innovative drug delivery solutions to its clients.
